- Business Wire•2 hours ago
Transgene and Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate TG4010 in Combination with Opdivo and Standard Chemotherapy in First Line Non-Small Cell Lung Cancer
Bristol-Myers Squibb Company and Transgene today announced a new clinical research collaboration to evaluate the safety, tolerability and efficacy of Transgene’s investigational therapeutic vaccine TG4010 in combination with Bristol-Myers Squibb’s Opdivo + standard chemotherapy as a first-line treatment for advanced non-squamous non-small cell lung cancer in patients whose tumors have low or undetectable ...
- Reuters•13 hours ago
Large drugmakers with piles of cash are on the hunt for promising medicines being developed by small companies to treat NASH, a progressive fatty liver disease poised to become the leading cause of liver ...
BMY : Summary for Bristol-Myers Squibb Company Co - Yahoo Finance
Bristol-Myers Squibb Company (BMY)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Day's Range||53.51 - 54.00|
|52 Week Range||46.01 - 77.12|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||20.21|
|Dividend & Yield||1.56 (2.95%)|
|1y Target Est||N/A|